<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
	"http://www.w3.org/TR/1998/REC-html40-19980424/loose.dtd">
<html>
<head><meta http-equiv="content-type" content="text/html; charset=UTF-8">
<style type="text/css">
 table.main {}
 tr.row {}
 td.cell {}
 div.block {}
 div.paragraph {}
 .font0 { font:6pt Arial, sans-serif; }
 .font1 { font:8pt Arial, sans-serif; }
 .font2 { font:10pt Arial, sans-serif; }
 .font3 { font:11pt Arial, sans-serif; }
 .font4 { font:17pt Arial, sans-serif; }
 .font5 { font:10pt Times New Roman, serif; }
 .font6 { font:13pt Times New Roman, serif; }

</style>
</head>
<body>
<p><span class="font6">J.P. Morgan</span></p>
<p><span class="font1">Asia Pacific Equity Research</span></p>
<p><span class="font0" style="font-weight:bold;">31 August 2015</span></p>
<p><span class="font0" style="font-weight:bold;">Leon Chik, CFA</span></p>
<p><span class="font0" style="font-weight:bold;">(852) 2800-8590</span></p>
<p><a href="mailto:leon.hk.chik@jpmorgan.com"><span class="font0" style="font-weight:bold;">leon.hk.chik@jpmorgan.com</span></a></p>
<p><span class="font4">Investment Thesis, Valuation and Risks</span></p>
<p><span class="font2" style="font-weight:bold;">Fufeng Group </span><span class="font2" style="font-style:italic;">(Overweight; Price Target: HK$6.50)</span></p>
<p><span class="font1" style="font-weight:bold;">Investment Thesis</span></p>
<p><span class="font5">Fufeng is the largest producer of monosodium glutamate (MSG) in China. We expect a moderate improvement in MSG margins driven by falling costs and a dearth of new supply.</span></p>
<p><span class="font1" style="font-weight:bold;">Valuation</span></p>
<p><span class="font5">Our Dec-16 price target is based on a DCF valuation, which assumes a market risk premium of 6.0% and a risk-free rate of 4.2% (yield on 10-year government notes in China). We assume a beta of 1.5, higher than the Bloomberg beta of 0.8, given that the company has seen significant sales growth as well as a large increase in its capacity over the past 1-2 years.</span></p>
<p><span class="font1" style="font-weight:bold;">Risks to Rating and Price Target</span></p>
<p><span class="font5">The key downside risks to our rating and price target include: 1) lower ASP and margins for xanthum gum as more competitors add capacity; 2) higher cost of com could crimp margins; and 3) concern over debt levels could rise with credit tightening in China.</span></p>
<p><span class="font3">This document is being provided for the exclusive use of </span><a href="mailto:huzaifa.merchant@jpmorgan.com"><span class="font3">huzaifa.merchant@jpmorgan.com</span></a><span class="font3"> &amp;&nbsp;clients of J.P. Morgan.</span></p>
</body>
</html>